<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment regimens for native valve endocarditis due to penicillin-susceptible viridans streptococci and &lt;EM innerHtml&gt;Streptococcus gallolyticus &lt;/EM&gt;&lt;EM&gt;(&lt;/EM&gt;&lt;EM innerHtml&gt;bovis)&lt;/EM&gt;*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment regimens for native valve endocarditis due to penicillin-susceptible viridans streptococci and <em innerhtml="">Streptococcus gallolyticus </em><em>(</em><em innerhtml="">bovis)</em>*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment regimens for native valve endocarditis due to penicillin-susceptible viridans streptococci and <em innerhtml="">Streptococcus gallolyticus </em><em>(</em><em innerhtml="">bovis)</em>*</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="2">American Heart Association (AHA)</td> <td class="subtitle1" rowspan="2"> <p> European Society of Cardiology (ESC)</p> <p>(MIC ≤0.125 mcg/mL)</p> </td> <td class="subtitle1" rowspan="2"> <p>British Society for Antimicrobial Chemotherapy (BSAC)</p> <p>(MIC ≤0.125 mcg/mL)</p> </td> </tr> <tr> <td class="subtitle2"> <p>Adult</p> <p>(MIC ≤0.12 mcg/mL)</p> </td> <td class="subtitle2"> <p>Pediatric</p> <p>(MIC ≤0.1 mcg/mL)</p> </td> </tr> <tr> <td class="subtitle2_left">4-week regimens<sup>¶</sup>:</td> <td class="subtitle2_left">4-week regimens:</td> <td class="subtitle2_left"> 4-week regimens<sup>Δ</sup>:</td> <td class="subtitle2_left">4- to 6-week regimens:</td> </tr> <tr> <td> <p>Aqueous penicillin G 12 to 18 million units per 24 hours IV either continuously or in 4 or 6 divided doses</p> <p><strong>or <strong>(if penicillin is unavailable)</strong></strong></p> <p>Ampicillin 2 g IV every 4 hours </p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV or IM in 1 dose</p> <p><strong>Beta-lactam-intolerant patients:</strong></p> <p><strong></strong>Vancomycin<sup>◊</sup> 30 mg/kg per 24 hours IV in 2 divided doses</p> </td> <td> <p>Aqueous penicillin G 200,000 to 300,000 units/kg per 24 hours IV in 6 divided doses (maximum dose: 24 million units per 24 hours)</p> <p><strong>or (if penicillin is unavailable)</strong></p> <p>Ampicillin 200 to 300 mg/kg per 24 hours IV divided in 4 or 6 divided doses (maximum dose: 12 g per 24 hours)</p> <p><strong>or</strong></p> <p>Ceftriaxone 100 mg/kg per 24 hours IV<sup>​§</sup> in 2 divided doses or 80 mg/kg in 1 daily dose (maximum dose: 4 g per 24 hours; if dose is &gt;2 g per 24 hours, use divided dosing every 12 hours)</p> <p><strong><strong>Beta-lactam-intolerant patients:</strong></strong></p> <p>Vancomycin<sup>◊</sup> 40 mg/kg per 24 hours IV in 2 or 3 divided doses (maximum dose: 2 g per 24 hours)</p> </td> <td>Aqueous penicillin G<sup>¶</sup> 12 to 18 million units per 24 hours IV in 4 or 6 divided doses or continuous infusion <p><strong>or</strong></p> <p>Amoxicillin 100 to 200 mg/kg per 24 hours IV in 4 to 6 divided doses</p> <p><strong>or</strong></p> <p>Ampicillin 12 g per 24 hours (or 100 to 200 mg/kg per 24 hours) IV in 6 divided doses</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>¶¥</sup> 2 g per 24 hours IV or IM in 1 dose</p> <p><strong>or</strong></p> <p>Vancomycin<sup>◊</sup> 30 mg/kg per 24 hours IV in 2 divided doses</p> </td> <td> <p>Benzylpenicillin<sup>‡</sup> 1.2 g every 4 hours IV</p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV/IM</p> </td> </tr> <tr> <td class="subtitle2_left">2-week regimens<sup>†</sup>:</td> <td class="subtitle2_left">2-week regimens<sup>†</sup>:</td> <td class="subtitle2_left">2-week regimens<sup>Δ†</sup>:</td> <td class="subtitle2_left">2-week regimens<sup>†</sup>:</td> </tr> <tr> <td> <p><strong>Either</strong></p> <p>Aqueous penicillin G 12 to 18 million units per 24 hours IV either continuously or in 6 divided doses</p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV or IM in 1 dose</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>**,¶¶</sup> 3 mg/kg per 24 hours IV or IM in 1 dose (preferred) or in 3 divided doses</p> </td> <td> <p>Not recommended for children due to lack of data</p> </td> <td> <p><strong>Either</strong></p> <p>Aqueous penicillin G 12 to 18 million units per 24 hours IV in 4 to 6 divided doses or continuous infusion</p> <p><strong>or</strong></p> <p>Amoxicillin 100 to 200 mg/kg per 24 hours IV in 4 to 6 divided doses</p> <p><strong>or</strong></p> <p>Ampicillin 12 g (or 100 to 200 mg/kg) per 24 hours IV in 6 divided doses</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>¶¥</sup> 2 g per 24 hours IV or IM in 1 dose</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>**,ΔΔ</sup> 3 mg/kg per 24 hours IV or IM in 1 dose</p> </td> <td> <p><strong>Either</strong></p> <p>Benzylpenicillin<sup>‡ </sup>1.2 g every 4 hours IV</p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV or IM</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>**</sup> 1 mg/kg every 12 hours IV</p> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The doses above are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the individual Lexicomp drug monographs for renal dose adjustments.<br/>​Wherever intramuscular administration is provided as an alternative, intravenous route is preferred, particularly in infants and children.</div><div class="graphic_footnotes">MIC: minimum inhibitory concentration; IV: intravenously; IM: intramuscularly.<br/>* MIC thresholds differ between guidelines. AHA adult guidelines use MIC ≤0.12 mcg/mL; AHA pediatric guidelines use MIC ≤0.1 mcg/mL. ESC and BSAC guidelines use MIC ≤0.125 mcg/mL.<br/>¶ Preferred in most patients &gt;65 years or with impairment of 8th nerve or renal function.<br/>Δ Pediatric doses (should not exceed adult doses): Penicillin G 200,000 units/kg per 24 hours IV in 4 to 6 divided doses; amoxicillin 300 mg/kg per 24 hours IV in 4 to 6 divided doses; ceftriaxone 100mg/kg per dose IV or IM daily; vancomycin 40 mg/kg per 24 hours IV in 2 or 3 divided doses; gentamicin 3 mg/kg per 24 hours IV or IM in a single daily dose or in 3 divided doses.<br/>◊ Vancomycin therapy only recommended for patients allergic to penicillin and cephalosporins; vancomycin dose adjusted for trough concentration of 10 to 15 mcg/mL. Penicillin desensitization can be attempted in stable patients. <br/>§ In infants and children, intravenous antibiotics are recommended rather than intramuscular agents.<br/>¥ Preferred for outpatient therapy.<br/>‡ Amoxicillin 2 g every 4 to 6 hours IV may be used in place of benzylpenicillin 1.2 to 2.4 g every 4 hours. <br/>† For noncomplicated infective endocarditis. Not intended for patients with known cardiac or extracardiac abscess or for creatinine clearance &lt;20 mL/min, impaired 8th nerve function, or infection due to <em>Abiotrophia</em>, <em innerhtml="">Granulicatella </em>spp, or <em>Gemella</em> spp.<br/>** Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dose adjusted for peak serum concentrations 3 to 4 mcg/mL, trough &lt;1 mcg/mL when 2 to 3 divided doses used; when given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per ESC guidelines, post-dose (peak, 1 hour after injection) serum concentrations should be approximately 10 to 12 mcg/mL (per AHA guidelines, there is no role for measuring peak gentamicin concentration following single daily dosing).<br/>¶¶ Gentamicin may be given as a single daily dose (3 mg/kg per day; preferred in outpatients) or in 2 to 3 equally divided doses (adjusted to achieve a peak serum level of 3 to 4 mcg/mL; preferred in hospitalized patients when serum concentrations can be followed).<br/>ΔΔ Netilmicin (4 to 5 mg/kg/day IV in 1 dose) is an alternative.</div><div class="graphic_reference">Data from:<br/><br/><ol>
<li>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</li>
<li>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</li>
<li>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</li>
<li>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</li></ol></div><div id="graphicVersion">Graphic 73007 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
